Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | CTSE | P14091 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.39 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31052491 | 0.90 | SRC (0.48) | GPR119USP30SRCEGFRCTSD | |
| SCHEMBL1557907 | 0.87 | CTSD (0.49) | GPR119CTSDCTSEBACE1 | |
| SCHEMBL25432161 | 0.85 | NR1H2 (0.40) | NR1H2NAMPTGPR119USP30RORC | |
| SCHEMBL31056160 | 0.84 | FPR2 (0.42) | NR1H2NAMPTGPR119USP30RORC | |
| SCHEMBL21063625 | 0.83 | USP30 (0.41) | NR1H2NAMPTGPR119USP30SRC | |
| SCHEMBL25308596 | 0.83 | PIK3CA (0.42) | NR1H2NAMPTGPR119USP30SRC | |
| SCHEMBL26090665 | 0.82 | NR1H2 (0.38) | NR1H2NAMPTGPR119USP30JAK3 | |
| SCHEMBL21063582 | 0.81 | NR1H2 (0.42) | NR1H2NAMPTGPR119USP30JAK3 | |
| SCHEMBL20743309 | 0.80 | KDM4A (0.40) | HDAC1HDAC2SMARCA2SMARCA4PBRM1 | |
| SCHEMBL15293710 | 0.80 | ALDH1A1 (0.44) | NR1H2NAMPTGPR119USP30RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103201277-B | Pyridazinone, its preparation method and using method | GILEAD CONNECTICUT, INC. (US) | 2015-11-25 | — | — | CN | disclosed |
| US-8975260-B2 | Pyridazinones, method of making, and method of use thereof | GENETECH, INC (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975260-B2 | Pyridazinones, method of making, and method of use thereof | GENETECH, INC (US) | 2015-03-10 | — | — | US | disclosed |
| US-20130261103-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GENENTECH, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261103-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GENENTECH, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| CN-103201277-A | Pyridazinones, method of making, and method of use thereof | GILEAD CONNECTICUT INC | 2013-07-10 | — | — | CN | disclosed |
| WO-2012030990-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261103-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, TYK2, LCK | NR1H2 1630/4885NAMPT 783/4885GPR119 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.